CTKB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cytek Biosciences Inc (CTKB) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite some positive catalysts such as revenue growth and product success, the company's financial performance shows significant net income and EPS declines, which raises concerns about profitability. Additionally, technical indicators and trading signals do not strongly support a buy decision at this time.
The MACD is above 0 but positively contracting, indicating a weak bullish signal. The RSI is neutral at 42.653, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support and resistance levels suggest limited immediate upside potential, with the pivot at 4.39 and resistance levels at 4.558 and 4.662.
Recurring revenue grew 21% YoY and accounted for 34% of total revenue. Revenue guidance for 2026 is between $205 million and $212 million.
Gross margin decreased by 9.62% YoY to 52.92%. No significant hedge fund or insider trading trends. Congress trading data is unavailable.
In Q4 2025, revenue increased by 8.12% YoY to $62.1 million, but net income dropped significantly to -$44.08 million (-557.08% YoY). EPS fell to -0.34 (-585.71% YoY), and gross margin declined to 52.92% (-9.62% YoY).
TD Cowen raised the price target to $5 from $4 and maintains a Buy rating, citing positive investor sentiment and multi-year growth potential. However, the stock's valuation and profitability concerns remain key challenges.
